Showing results (31-40 of 67) with videos related to
Sort By:
Pageof 7
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reasonGiammarco Mocci, Arianna Cingolani, Giorgia Orrù, et al.Journal of Clinical Medicine|June 13, 2025
Clinical and Genetic Characteristics of Pediatric Patients with Inflammatory Bowel Disease Transitioning to Adult Medicine: A Single-Center Ten-Year ExperienceGiammarco Mocci, Giorgia Orrù, Francesca Maria Onidi, et al.Inflammatory Bowel Diseases|April 2, 2019
Comparative Efficacy of Vedolizumab and Adalimumab in Ulcerative Colitis Patients Previously Treated With InfliximabAgnese Favale, Sara Onali, Flavio Caprioli, et al.United European Gastroenterology Journal|December 1, 2020
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort studyStefano Festa, Maria L Scribano, Daniela Pugliese, et al.Journal of Gastrointestinal and Liver Diseases : JGLD|September 19, 2017
Effectiveness and Safety of Golimumab in Treating Outpatient Ulcerative Colitis: A Real-Life Prospective, Multicentre, Observational Study in Primary Inflammatory Bowel Diseases CentersAntonio Tursi, Leonardo Allegretta, Nello Buccianti, et al.Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 18, 2019
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD studyDaniela Pugliese, Marco Daperno, Gionata Fiorino, et al.United European Gastroenterology Journal|December 17, 2025
Performance of GPT-5 in the Interpretation of IBD Histopathology ReportsMarcello Maida, Alessandro Vitello, Fabio Salvatore Macaluso, et al.Annals of Gastroenterology|July 3, 2019
Infliximab biosimilar CT-P13 is effective and safe in treating inflammatory bowel diseases: a real-life multicenter, observational study in Italian primary inflammatory bowel disease centersAntonio Tursi, Giammarco Mocci, Roberto Faggiani, et al.World Journal of Clinical Cases|November 7, 2022
Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter studySalvatore Magrì, Mauro Demurtas, Maria Francesca Onidi, et al.Medicine|August 26, 2018
Effectiveness and safety of adalimumab to treat outpatient ulcerative colitis: A real-life multicenter, observational study in primary inflammatory bowel disease centersAntonio Tursi, Walter Elisei, Roberto Faggiani, et al.Pageof 7